BiotechTube

Eltrombopag

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Purpura, Thrombocytopaenic, Idiopathic

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Trial Timeline

Dec 21, 2010 → Oct 16, 2020

NCT ID
NCT01416311

About Eltrombopag

Eltrombopag is a pre-clinical stage product being developed by Novartis for Purpura, Thrombocytopaenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT01416311. Target conditions include Purpura, Thrombocytopaenic, Idiopathic.

What happened to similar drugs?

1 of 20 similar drugs in Purpura, Thrombocytopaenic, Idiopathic were approved

Approved (1) Terminated (1) Active (18)
❌Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
🔄Hetrombopag Olamine + matching placeboJiangsu Hengrui MedicinePhase 3
🔄EltrombopagNovartisPhase 3
🔄eltrombopag + placeboNovartisPhase 3
🔄Eltrombopag + IVIG infusionNovartisPhase 3
🔄eltrombopag olamine (SB-497115-GR)NovartisPhase 3
🔄Eltrombopag Tablets + Eltrombopag PfOSNovartisPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT04837703Pre-clinicalActive
NCT05286164Phase 2UNKNOWN
NCT03988608Phase 2Completed
NCT03718533Phase 2Terminated
NCT03664518Phase 2Completed
NCT03524612Phase 2Completed
NCT02877212Phase 3UNKNOWN
NCT02323178Phase 1/2Completed
NCT01703169Phase 2Completed
NCT01715779Pre-clinicalCompleted
NCT01416311Pre-clinicalCompleted

Competing Products

20 competing products in Purpura, Thrombocytopaenic, Idiopathic

See all competitors
ProductCompanyStageHype Score
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oralEisaiPhase 1
29
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Hetrombopag Olamine + matching placeboJiangsu Hengrui MedicinePhase 3
40
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
25
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
25
MK-8723 + Matching PlaceboMerckPhase 1
29
EltrombopagNovartisPhase 2
35
eltrombopagNovartisPhase 2
35
EltrombopagNovartisPhase 3
36
eltrombopag + placeboNovartisPhase 3
40
Eltrombopag + IVIG infusionNovartisPhase 3
40
eltrombopag olamine (SB-497115-GR)NovartisPhase 3
40
Eltrombopag Tablets + Eltrombopag PfOSNovartisPhase 3
40